NKGen Biotech(NKGN)

Search documents
NKGen Biotech(NKGN) - 2022 Q2 - Quarterly Report
2022-08-15 20:50
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) | Delaware | 001-40427 | 86-2191918 | | --- | --- | --- | ...
NKGen Biotech(NKGN) - 2022 Q1 - Quarterly Report
2022-05-16 20:10
IPO and Fundraising - The company completed its IPO on May 25, 2021, raising gross proceeds of $150.0 million from the sale of 15,000,000 units at $10.00 per unit[103] - An additional 2,161,500 units were sold through the over-allotment option, generating approximately $21.6 million in gross proceeds[103] - The company has placed $171.6 million in a trust account, which will be invested in U.S. government securities until a business combination is completed[105] Financial Performance - As of March 31, 2022, the company reported a net income of approximately $2.0 million, primarily from a non-operating gain of approximately $2.7 million due to changes in the fair value of warrant liability[114] - The company incurred approximately $638,000 in general and administrative expenses for the three months ended March 31, 2022[114] - Diluted net income (loss) per share for the three months ended March 31, 2022, is the same as basic net income (loss) per share due to the anti-dilutive effect of warrants[130] Financial Position - The company had a working capital deficit of approximately $90,000 as of March 31, 2022[108] - As of March 31, 2022, the company had approximately $1.4 million in its operating bank account[108] - The company has no long-term debt obligations or capital lease obligations as of March 31, 2022[117] - As of March 31, 2022, the company did not have any off-balance sheet arrangements[133] Going Concern and Compliance - The company expects to incur increased expenses related to being a public company, including legal and compliance costs[113] - The company has determined that there is substantial doubt about its ability to continue as a going concern within one year after the date of the financial statements[110] Corporate Governance - On May 1, 2022, key executives including the Chief Financial Officer and Co-Presidents announced their resignations, effective May 6 and May 11, 2022[136] Regulatory Status - The company qualifies as an "emerging growth company" under the JOBS Act, allowing it to delay the adoption of new or revised accounting standards[134] - The company is evaluating the benefits of relying on reduced reporting requirements provided by the JOBS Act, which may exempt it from certain disclosures for five years post-IPO[135]
NKGen Biotech(NKGN) - 2021 Q4 - Annual Report
2022-03-31 01:27
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ( ...
NKGen Biotech(NKGN) - 2021 Q3 - Quarterly Report
2021-11-15 21:13
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) | Delaware | 001-40427 | 86-2191918 | | --- | --- | ...
NKGen Biotech(NKGN) - 2021 Q2 - Quarterly Report
2021-08-16 20:55
(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) Delaware 001-40427 86-2191918 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number) ...
NKGen Biotech(NKGN) - 2021 Q1 - Quarterly Report
2021-07-02 20:11
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiz ...